QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more
QuiaPEG Pharmaceuticals Holding AB (QUIA) - Net Assets
Latest net assets as of June 2025: Skr6.47 Million SEK
Based on the latest financial reports, QuiaPEG Pharmaceuticals Holding AB (QUIA) has net assets worth Skr6.47 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr15.28 Million) and total liabilities (Skr8.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.47 Million |
| % of Total Assets | 42.35% |
| Annual Growth Rate | -0.59% |
| 5-Year Change | 22933.8% |
| 10-Year Change | 136.3% |
| Growth Volatility | 2769.12 |
QuiaPEG Pharmaceuticals Holding AB - Net Assets Trend (2008–2024)
This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for QuiaPEG Pharmaceuticals Holding AB (2008–2024)
The table below shows the annual net assets of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr16.35 Million | +7.23% |
| 2023-12-31 | Skr15.25 Million | +532.30% |
| 2022-12-31 | Skr2.41 Million | +10863.64% |
| 2021-12-31 | Skr22.00K | -69.01% |
| 2020-12-31 | Skr71.00K | +100.83% |
| 2019-12-31 | Skr-8.57 Million | -1672.84% |
| 2018-12-31 | Skr545.00K | -90.97% |
| 2017-12-31 | Skr6.04 Million | -67.26% |
| 2016-12-31 | Skr18.44 Million | +166.45% |
| 2015-12-31 | Skr6.92 Million | +7.44% |
| 2014-12-31 | Skr6.44 Million | -11.07% |
| 2013-12-31 | Skr7.24 Million | -25.56% |
| 2012-12-31 | Skr9.73 Million | -30.38% |
| 2011-12-31 | Skr13.98 Million | -18.58% |
| 2010-12-31 | Skr17.17 Million | -3.65% |
| 2009-12-31 | Skr17.82 Million | -0.88% |
| 2008-12-31 | Skr17.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to QuiaPEG Pharmaceuticals Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3617.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr23.78 Million | 145.43% |
| Other Comprehensive Income | Skr16.64 Million | 101.77% |
| Other Components | Skr17.78 Million | 108.73% |
| Total Equity | Skr16.35 Million | 100.00% |
QuiaPEG Pharmaceuticals Holding AB Competitors by Market Cap
The table below lists competitors of QuiaPEG Pharmaceuticals Holding AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Point of Care Nano-Technology Inc
PINK:PCNT
|
$61.86K |
|
DALATA HOTEL (DHG.SG)
STU:DHG
|
$61.90K |
|
176750
KO:176750
|
$61.92K |
|
JOST (JOX.SG)
STU:JOX
|
$61.97K |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
$61.78K |
|
XMax Inc.
NASDAQ:XWIN
|
$61.78K |
|
StageZero Life Sciences Ltd
PINK:SZLSF
|
$61.77K |
|
KARO INVEST a.s.
PR:KARIN
|
$61.76K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in QuiaPEG Pharmaceuticals Holding AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,251,000 to 16,354,000, a change of 1,103,000 (7.2%).
- Net loss of 28,929,000 reduced equity.
- New share issuances of 23,432,000 increased equity.
- Other comprehensive income decreased equity by 3,284,000.
- Other factors increased equity by 9,884,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-28.93 Million | -176.89% |
| Share Issuances | Skr23.43 Million | +143.28% |
| Other Comprehensive Income | Skr-3.28 Million | -20.08% |
| Other Changes | Skr9.88 Million | +60.44% |
| Total Change | Skr- | 7.23% |
Book Value vs Market Value Analysis
This analysis compares QuiaPEG Pharmaceuticals Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr285.21 | Skr0.00 | x |
| 2009-12-31 | Skr365.70 | Skr0.00 | x |
| 2010-12-31 | Skr352.34 | Skr0.00 | x |
| 2011-12-31 | Skr287.85 | Skr0.00 | x |
| 2012-12-31 | Skr199.71 | Skr0.00 | x |
| 2013-12-31 | Skr148.67 | Skr0.00 | x |
| 2014-12-31 | Skr97.74 | Skr0.00 | x |
| 2015-12-31 | Skr142.04 | Skr0.00 | x |
| 2016-12-31 | Skr327.04 | Skr0.00 | x |
| 2017-12-31 | Skr47.50 | Skr0.00 | x |
| 2018-12-31 | Skr2.13 | Skr0.00 | x |
| 2019-12-31 | Skr-27.76 | Skr0.00 | x |
| 2020-12-31 | Skr0.17 | Skr0.00 | x |
| 2021-12-31 | Skr0.04 | Skr0.00 | x |
| 2022-12-31 | Skr1.36 | Skr0.00 | x |
| 2023-12-31 | Skr0.20 | Skr0.00 | x |
| 2024-12-31 | Skr0.04 | Skr0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently QuiaPEG Pharmaceuticals Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -176.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6288.91%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.39x
- Recent ROE (-176.89%) is above the historical average (-8243.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 4.19% | 8.21% | 0.43x | 1.19x | Skr-1.04 Million |
| 2009 | 0.27% | 0.47% | 0.49x | 1.16x | Skr-1.73 Million |
| 2010 | 0.43% | 0.76% | 0.49x | 1.16x | Skr-1.64 Million |
| 2011 | 2.68% | 2.96% | 0.73x | 1.24x | Skr-1.03 Million |
| 2012 | -31.70% | -31.82% | 0.56x | 1.79x | Skr-4.06 Million |
| 2013 | -23.08% | -12.81% | 1.14x | 1.59x | Skr-2.40 Million |
| 2014 | -10.46% | -7.27% | 0.90x | 1.60x | Skr-1.32 Million |
| 2015 | 8.35% | 4.01% | 1.62x | 1.28x | Skr-114.10K |
| 2016 | 52.03% | 1047.49% | 0.04x | 1.20x | Skr7.75 Million |
| 2017 | -74.00% | -113.63% | 0.31x | 2.11x | Skr-5.07 Million |
| 2018 | -2211.38% | -356.88% | 0.36x | 17.11x | Skr-12.11 Million |
| 2019 | 0.00% | -472.62% | 0.29x | 0.00x | Skr-20.25 Million |
| 2020 | -39028.17% | -1488.98% | 0.09x | 289.32x | Skr-27.72 Million |
| 2021 | -97526.09% | -10384.72% | 0.01x | 1033.22x | Skr-22.43 Million |
| 2022 | -1010.95% | -437.46% | 0.24x | 9.72x | Skr-24.63 Million |
| 2023 | -108.34% | -377.75% | 0.10x | 2.75x | Skr-18.05 Million |
| 2024 | -176.89% | -6288.91% | 0.02x | 1.39x | Skr-30.56 Million |
Industry Comparison
This section compares QuiaPEG Pharmaceuticals Holding AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| QuiaPEG Pharmaceuticals Holding AB (QUIA) | Skr6.47 Million | 4.19% | 1.36x | $61.82K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |